Personalis, Inc. to Present at the World Immunotherapy Congress USA 2019

Menlo Park, CA – February 28, 2019 – Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that they are scheduled to present at the upcoming World Immunotherapy Congress USA, which is part of the Festival of Biologics USA, in San Diego on Tuesday, March 5, 2019 at 2:20 PM, PST.

The presentation, entitled “Comprehensive Immunogenomics for Biomarker Discovery from a Single Sample,” will introduce Personalis’ new universal cancer immunogenomics platform, ImmunoID NeXT™, and will discuss how this platform can be used to overcome the challenges facing immuno-oncology translational and clinical researchers to ultimately enable the development of safer, more effective precision oncology therapeutics and combinations.

ImmunoID NeXT is the first and only platform to provide comprehensive analysis of both a tumor and its microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology; consolidating multiple oncology biomarker assays into one. This maximizes the biological information that can be generated from a precious tumor specimen.

The presentation will be delivered by Kedar Hastak, PhD, Field Application Scientist.

About Personalis, Inc.

Personalis, Inc. is a leader in advanced genomics for precision oncology translational research and clinical trials, dedicated to enabling the development of the next generation of oncology therapeutics. The company’s ImmunoID NeXT Platform comprehensively characterizes the tumor and the tumor microenvironment, facilitating the analysis of key predictive and investigational oncology biomarkers from a single sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300